IP Library › Granted Patent US 12,226,402
Granted Patent B2
US 12,226,402 · App. 18/516,458 · Granted Feb 18, 2025

Dual inhibitors of TIM-3 and PD-1 pathways

Inventors: Pottayil Govindan Nair Sasikumar (Bangalore, IN); Muralidhara Ramachandra (Bangalore, IN); Seetharamaiah Setty Sudarshan Naremaddepalli (Bangalore, IN); Nagaraj Gowda (Bangalore, IN)
Assignee: Aurigene Oncology Limited
A61K31/4245A61K31/454A61K31/5377A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,402
App. No.
18/516,458
Granted
Feb 18, 2025
Kind
B2
Abstract

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

Claims (15)

1. A method of modulating an immune response mediated by T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) activity in a subject, comprising administering to the subject a compound, wherein the compound is

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

4. The method of claim 1 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway.

5. The method of claim 2 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway.

6. The method of claim 3 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway.

7. The method of claim 1 , wherein the subject is suffering from a disease or disorder selected from cancer, an immune disorder, an immunodeficiency disorder, an inflammatory disorder, an infectious disease, and transplant rejection; and the method treats the disease or disorder.

8. The method of claim 7 , wherein the disease or disorder is cancer.

9. The method of claim 8 , wherein the cancer is selected from breast cancer, colon cancer, liver cancer, ovarian cancer, prostate cancer, renal cancer, and uterine cancer.

10. The method of claim 8 , wherein the cancer is a hematopoietic cancer.

11. The method of claim 10 , wherein the hematopoietic cancer is selected from lymphoma, B cell lymphoma, T cell lymphoma, Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, a leukemia, a myeloma, acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphoblastic leukemia (CLL), chronic myelomonocytic leukemia (CMML), multiple myeloma, myelodysplastic syndrome (MDS), and plasmacytoma.

12. The method of claim 8 , wherein the cancer is selected from ovarian cancer, colon cancer, breast cancer, lung cancer, a myeloma, a neuroblastic-derived CNS tumor, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, a B-cell derived lymphoma, a T-cell derived lymphoma, and a mast cell derived tumor.

13. The method of claim 8 , wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, connective tissue cancer, eye cancer, throat cancer, oral cavity cancer, biliary tract cancer, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, endometrial cancer, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, thyroid cancer, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), myeloproliferative disorder/neoplasm (MPDS), myelodysplasia syndrome, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, solid tumors of childhood, a B-cell derived lymphoma, T-cell derived lymphoma, Hodgkin's lymphoma, indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, follicular lymphoma, mesothelioma, thymic carcinoma, myeloma, multiple myeloma, giant cell myeloma, heavy-chain myeloma, light chain or Bence-Jones myeloma, a mast cell derived tumor, leiomyoma, leiomyosarcoma, glioma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neuroblastic-derived CNS tumors, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, Meigs' syndrome, Merkel cell carcinoma, and environmentally induced cancers.

14. The method of claim 7 , wherein the disease or disorder is an immune disorder, immunodeficiency disorder, or an inflammatory disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: SASIKUMAR, POTTAYIL GOVINDAN NAIR; RAMACHANDRA, MURALIDHARA; NAREMADDEPALLI, SEETHARAMAIAH SETTY S.; GOWDA, NAGARAJ
To: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Reel/Frame 067434/0990 →
CHANGE OF NAME Recorded May 16, 2024
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 067435/0019 →
Priority Claims (1)
IN 201741039298 · Nov 3, 2017 · national
Continuity (3)
Continuation 17962096 · Oct 7, 2022
Continuation 16761162
Related Publication 20240100024A1 · Mar 28, 2024
References Cited (185)
US 3227725A · Fernand et al. · 1966 [cited by applicant]
US 5387585A · Borer et al. · 1995 [cited by applicant]
US 5665718A · Godel et al. · 1997 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 9771338B2 · Sasikumar et al. · 2017 [cited by applicant]
US 10173989B2 · Sasikumar et al. · 2019 [cited by applicant]
US 10590093B2 · Sasikumar et al. · 2020 [cited by applicant]
US 10781189B2 · Sasikumar et al. · 2020 [cited by applicant]
US 10961205B2 · Sasikumar et al. · 2021 [cited by applicant]
US 11040948B2 · Yu · 2021 [cited by applicant]
US 11136300B2 · Sasikumar et al. · 2021 [cited by applicant]
US 11465976B2 · Sasikumar et al. · 2022 [cited by applicant]
US 11497734B2 · Sasikumar et al. · 2022 [cited by applicant]
US 11497735B2 · Sasikumar et al. · 2022 [cited by applicant]
US 11939306B2 · Yu · 2024 [cited by applicant]
US 12064418B2 · Sasikumar et al. · 2024 [cited by applicant]
US 20050272779A1 · Edwards et al. · 2005 [cited by applicant]
US 20070197522A1 · Edwards et al. · 2007 [cited by applicant]
US 20070225332A1 · Gu et al. · 2007 [cited by applicant]
US 20090099227A1 · Fyfe et al. · 2009 [cited by applicant]
US 20110275673A1 · Xiang et al. · 2011 [cited by applicant]
US 20130022629A1 · Sharpe et al. · 2013 [cited by applicant]
US 20140199334A1 · Sasikumar et al. · 2014 [cited by applicant]
US 20140235620A1 · Caferro et al. · 2014 [cited by applicant]
US 20150073024A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150073042A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20180044303A1 · Sasikumar et al. · 2018 [cited by applicant]
US 20200061030A1 · Sasikumar et al. · 2020 [cited by applicant]
US 20200239422A1 · Sasikumar et al. · 2020 [cited by applicant]
US 20200247766A1 · Yu · 2020 [cited by applicant]
US 20200289477A1 · Sasikumar et al. · 2020 [cited by applicant]
US 20200368210A1 · Sasikumar et al. · 2020 [cited by applicant]
US 20210380544A1 · Yu · 2021 [cited by applicant]
US 20220048875A1 · Sasikumar et al. · 2022 [cited by applicant]
US 20240182433A1 · Yu · 2024 [cited by applicant]
JP 2016532710A · 2016 [cited by applicant]
JP 2016539662A · 2016 [cited by applicant]
KR 20160081897A · 2016 [cited by applicant]
WO WO200114557A1 · 2001 [cited by applicant]
WO WO2002079499A1 · 2002 [cited by applicant]
WO WO2002086083A2 · 2002 [cited by applicant]
WO WO2003042402A2 · 2003 [cited by applicant]
WO WO2003070711A1 · 2003 [cited by applicant]
WO WO2004004771A1 · 2004 [cited by applicant]
WO WO2004056875A1 · 2004 [cited by applicant]
WO WO2005056550A2 · 2005 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2006133216A2 · 2006 [cited by applicant]
WO WO2007075749A2 · 2007 [cited by applicant]
WO WO2008011557A2 · 2008 [cited by applicant]
WO WO2008039431A2 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO WO2009006555A2 · 2009 [cited by applicant]
WO WO2009059162A1 · 2009 [cited by applicant]
WO WO2009105712A1 · 2009 [cited by applicant]
WO WO2010051447A1 · 2010 [cited by applicant]
WO WO2010077634A1 · 2010 [cited by applicant]
WO WO2011066389A1 · 2011 [cited by applicant]
WO WO2011082400A2 · 2011 [cited by applicant]
WO WO2011137587A1 · 2011 [cited by applicant]
WO WO2011161699A2 · 2011 [cited by applicant]
WO WO2012129564A2 · 2012 [cited by applicant]
WO WO2012168944A1 · 2012 [cited by applicant]
WO WO2013132317A1 · 2013 [cited by applicant]
WO WO2013144704A1 · 2013 [cited by applicant]
WO WO2014055897A2 · 2014 [cited by applicant]
WO WO2014059173A2 · 2014 [cited by applicant]
WO WO2014100079A1 · 2014 [cited by applicant]
WO WO2014110298A1 · 2014 [cited by applicant]
WO WO2014141104A1 · 2014 [cited by applicant]
WO WO2014147586A1 · 2014 [cited by applicant]
WO WO2015033299A1 · 2015 [cited by applicant]
WO WO2015033301A1 · 2015 [cited by applicant]
WO WO2016073470A1 · 2016 [cited by applicant]
WO WO2016142833A1 · 2016 [cited by applicant]
WO WO2016142852A1 · 2016 [cited by applicant]
WO WO2016142886A2 · 2016 [cited by applicant]
WO WO2018047143A1 · 2018 [cited by applicant]
WO WO2018073754A1 · 2018 [cited by applicant]
WO WO2019061324A1 · 2019 [cited by applicant]
WO WO2019067678A1 · 2019 [cited by applicant]
WO WO2019087087A1 · 2019 [cited by applicant]
Alsaab et al., “PD-1 and PD-L1 Checkpoint Signaling Inhibition for CancerImmunotherapy: Mechanism, Combinations, and Clinical Outcome” Frontiers in Pharmacology, vol. 8, No. 561 (2017). [cited by applicant]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation,” Immunity, 44(5): 989-1004 (2016). [cited by applicant]
Ansell, “PD-1 Is Expressed on B-Cells in Waldenstrom Macroglobulinemia and Promotes Malignant Cell Viability and Proliferation” Blood, vol. 124, No. 21 (2014). [cited by applicant]
Ardestani et al., “Cell death features induced in Leishmania major by 1,3,4-thiadiazole derivatives,” Exp Parasitol, 132(2): 116-122 (2012). [cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1):1-19 (1977). [cited by applicant]
Booher et al., “Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model”, Blood, 130(1): 1534, (2017). [cited by applicant]
Borg et al., “1,2,4-Oxadiazole Derivatives of Phenylalnine: Potential Inhibitors of Substance P Endopeptidase,” Eur. J. Med. Chem., 28(10):801-810 (1993). [cited by applicant]
Brittain. “Polymorphism in pharmaceutical solids,” edited by H.G Brittain, D.J.W. Grant (chapter 1) p. 1-10 and J.K. Guillory (Chapter 5) p. 183-226 (1999). [cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12(7):945-954 (1995). [cited by applicant]
CAS Registry No. 1252104-30-5 (2013). [cited by applicant]
CAS Registry No. 1356744-17-6 (2012). [cited by applicant]
CAS Registry No. 146429-76-5 (2013). [cited by applicant]
CAS Registry No. 1494629-78-5 (2013). [cited by applicant]
CAS Registry No. 1496514-97-6 (2013). [cited by applicant]
CAS Registry No. 1496518-51-4 (2013). [cited by applicant]
CAS Registry No. 1557852-63-7 (2014). [cited by applicant]
CAS Registry No. 1848907-06-1 (2016). [cited by applicant]
CAS Registry No. 1848909-97-6 (2016). [cited by applicant]
CAS Registry No. 1857027-85-0 (2016). [cited by applicant]
CAS Registry No. 1868314-35-5 (2016). [cited by applicant]
CAS Registry No. 1868388-36-6 (2016). [cited by applicant]
CAS Registry No. 1868393-26-3 (2016). [cited by applicant]
CAS Registry No. 1869758-25-7 (2016). [cited by applicant]
CAS Registry No. 1870159-31-1 (2016). [cited by applicant]
CAS Registry No. 1875311-16-2 (2016). [cited by applicant]
CAS Registry No. 1875758-09-0 (2016). [cited by applicant]
CAS Registry No. 1878569-90-4 (2016). [cited by applicant]
CAS Registry No. 876710-85-9 (2006). [cited by applicant]
Cedres et al., “Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)” Plos One DOI:10.1371 (2015). [cited by applicant]
Censi et al., “Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs,” Molecules, 20(10): 18759-18776 (2015). [cited by applicant]
Clinical Trial NCT 02812875., “A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas,” U.S. National Library of Medicine: 7 pages (2016). [cited by applicant]
Clinical Trial NCT02671955., “A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer,” U.S. National Library of Medicine: 9 pages (2016). [cited by applicant]
Curiel et al., “Blockade of B7-H1 improves myeloid dendritic cell-mediated anitumor immunity” Nature Medicine, vol. 9, No. 5 (2003). [cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 172410-37-6. [cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 197083-27-5. [cited by applicant]
Dempke et al., “Second-and third-generation drugs for immuno-oncology treatment—The more the better?” Eur J Cancer, 74: 55-72 (2017). [cited by applicant]
Deng et al., “A New VISTA on combination therapy for negative checkpoint regulator blockade” Journal for Immunotherapy of Cancer, 4(86): 1-7 (2016). [cited by applicant]
Extended European Search Report for EP Application No. 16761169.8 mailed Jul. 2, 2019. [cited by applicant]
Extended European Search Report for EP Application No. 16761184 mailed Jun. 26, 2018. [cited by applicant]
Extended European Search Report for EP Application No. 17862427.6 dated Jun. 5, 2020. [cited by applicant]
Extended European Search Report for EP Application No. 21209727.3 dated May 18, 2022. [cited by applicant]
Extended European Search Report for EP Application No. EP/US18/18863750 mailed May 31, 2021. [cited by applicant]
Extended European Search Report for European Application No. 18162983.3 dated Jun. 27, 2018. [cited by applicant]
Graham, “Clinical Trials of HIV Vaccines,” HIV Molecular Immunology Database 2000. Edited by: Korber BT, Brander C, Haynes BF, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins D. Published by: Theoretical Biology and … [cited by applicant]
Guo et al., “Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists,” Bioorg Med Chem Letts 22(7):2572-2578 (2012). [cited by applicant]
Harvey, “Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer,” Nature, 96: 214-223 (2014). [cited by applicant]
Hirayama “Handbook for preparation of crystal of organic compound”, Maruzen Co., Ltd 17-23, 37-40, 45-51, 57-65 (2008). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2018/058526 mailed May 14, 2020. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CN2017/104485 dated Jun. 29, 2018. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2014/064279 mailed Dec. 12, 2014. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051266 mailed Jul. 8, 2016. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051343 mailed Jul. 28, 2016. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2017/056462 dated Jan. 10, 2018. [cited by applicant]
International Search Report Written Opinion for International Application No. PCT/US2018/053052 dated Jan. 29, 2019. [cited by applicant]
Jin, “Role of PD-1 in Regulating T-Cell Immunity,” Current Topics in Microbiology and Immunology, 350: 17-37 (2010). [cited by applicant]
Lazorchak et al., “Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer,” Cancer Immunol… [cited by applicant]
Lee, “A practical guide to pharmaceutical polymorph screening & selection,” Asian J Pharm Sci, 9(4): 163-175 (2014). [cited by applicant]
Liu et al., “Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T- cell responses,” PNAS, 112(21): 6682-6687 (2015). [cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,” Cell, 136(5): 823-837 (2009). [cited by applicant]
Marechal et al., “1,2,4-oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome,” Curr Med Chem 20(18):2351-2362 (2013). [cited by applicant]
Melero, “Evolving Synergistic Combinations of Targeted Immunotherapies to Combat Cancer”, Nature Reviews Cancer 15:457-472 (2015). [cited by applicant]
Moussebois et al., “Synthese de Deux Nouveaux Acides Amines Phenoliques Comportant un Cycle 1,2,4-Oxadiazole,” Helv. Chim. ACTA, 60(1):237-242 (1977). [cited by applicant]
Newman, “Specialized Solid Form Screening Techniques,” Org Process Res Dev, 13(3): 457-471 (2012). [cited by applicant]
Ozcan et al., “Oxadiazole-Isopropylamieds as Potent and Noncovalent Proteasome Inhibitors,” J. Med. Chem., 56(10):3783-3805 (2013). [cited by applicant]
Palazzo et al., “1,2,4-Oxadiazoles—IV. Synthesis and Pharmacological Properties of a Series of Substituted Aminoalkyl- 1,2,4-Oxadiazoles,” J. Med. Chem., 351-367 (1961). [cited by applicant]
Patwardhan et al., “Structure-Activity Relationship Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase Inhibitors: Discovery of SphK1- and SphK2—Selective Inhibitors,” J. Med. Chem., 58(4):1879-1899 (201… [cited by applicant]
Pedoeem et al., “Programmed Death-1 Pathway in Cancer and Autoimmunity,” Clinical Immunology, 153: 145-152 (2014). [cited by applicant]
Rabadi et al., ““The role of VISTA in the tumor microenvironment”” Journal of Cancer Metastasis and Treatment, 8(24): 1-14 (2022). [cited by applicant]
Rietz et al., “Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3),” J Med Chem, 64: 14757-14772 (2021). [cited by applicant]
Sasikumar et al., “PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy,” Communications Biology, 4: 12 pages (2021). [cited by applicant]
Shi et al., “The Role of PD-1 and PD-L1 in T-cell Immune Suppression in Patients with Hematological Malignancies,” Journal of Hematology & Oncology, 6(74): 1-6 (2013). [cited by applicant]
Skrdla et al., “A Simple Quantitative FT-IR Approach for the Study of a Polymorphic Transformation Under Crystallization Slurry Conditions”, Journal of Pharmaceutical and Biomedical Analysis, 25(5-6): 731-739 (2001). [cited by applicant]
Sureshbabu et al., “Synthesis of 1,2,4-oxadiazole-linked Orthogonally Urethane-Protected Dipeptide Mimetics,” Tetrahedron Letters, 49(35): 5133-5136 (2008). [cited by applicant]
Swaika et al., “Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy” Molecular Immunology (2015). [cited by applicant]
Tagliamento et al., “VISTA: A Promising Target for Cancer Immunotherapy?” ImmunoTargets and Therapy, 10: 185-200 (2021). [cited by applicant]
Takada, “API form screening and selection in drug discovery stage”, Pharm Stage, 6(10):20-25. (2007). [cited by applicant]
Waldmann, “Effective Cancer Therapy Through Immunomodulation,” T Annu Rev Med, 57: 65-81 (2006). [cited by applicant]
Wu et al., “VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses,” RSC Med Chem, 12: 1672-1679 (2021). [cited by applicant]
U.S. Appl. No. 15/556,800, Granted. [cited by applicant]
U.S. Appl. No. 16/945,854, Granted. [cited by applicant]
U.S. Appl. No. 17/962,976, Pending. [cited by applicant]
U.S. Appl. No. 15/298,539, Granted. [cited by applicant]
U.S. Appl. No. 15/713,671, Granted. [cited by applicant]
U.S. Appl. No. 16/192,030, Granted. [cited by applicant]
U.S. Appl. No. 16/806,872, Granted. [cited by applicant]
U.S. Appl. No. 17/192,279, Granted. [cited by applicant]
U.S. Appl. No. 17/981,695, Pending. [cited by applicant]
U.S. Appl. No. 16/343,681, Pending. [cited by applicant]
U.S. Appl. No. 16/761,162, Granted. [cited by applicant]
U.S. Appl. No. 17/962,096, Allowed. [cited by applicant]
U.S. Appl. No. 16/651,830, Granted. [cited by applicant]
U.S. Appl. No. 17/350,445, Granted. [cited by applicant]
U.S. Appl. No. 18/101,387, Allowed. [cited by applicant]
U.S. Appl. No. 16/755,439, Granted. [cited by applicant]
U.S. Appl. No. 17/461,512, Granted. [cited by applicant]
U.S. Appl. No. 18/197,414, Pending. [cited by applicant]
U.S. Appl. No. 16/761,964, Granted. [cited by applicant]
U.S. Appl. No. 17/960,586, Pending. [cited by applicant]
Lazorchak et al., “An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Journal for Immunothe… [cited by applicant]
Lazorchak et al., “An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Published by Curis, N… [cited by applicant]
LeMercier et al., “VISTA regulates the development of protective antitumor immunity.” Cancer Research 74(7) (2014): 1933-1944. [cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Cancer Research 76.14 (Jul. 31, 2016). [cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Published by Curis, Oct. 1, 2019. [cited by applicant]
Cited By (1)
US 12,643,870